Phaseline

Companies › Eclipse Life Sciences

Eclipse Life Sciences: clinical trials, targets and expected readouts

1 active drug program in 2 registered trials: 2 Phase 1; Ophthalmology; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
EC-104-6M high-dose
Corticosteroid (fluocinolone acetonide) intravitreal implant
–Phase 1Diabetic Macular EdemaDec 2026

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06536491EC-104-6M high-dosePhase 1Diabetic Macular EdemaOphthalmologyDec 2026
NCT06536491EC-104-6M high-dosePhase 1Diabetic Macular EdemaOphthalmologyDec 2026

From the company's SEC filings

Private offerings reported to the SEC (Form D)

Targets

No annotated target.

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.